Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) fell 3.8% on Thursday . The stock traded as low as $15.33 and last traded at $15.52, with a volume of 127,375 shares changing hands. The stock had previously closed at $16.14.

A number of research firms have recently commented on ADMS. Noble Financial reissued a “buy” rating and issued a $25.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 28th. Credit Suisse Group AG reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 22nd. Mizuho reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, June 23rd. JMP Securities reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $44.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $33.60.

The company’s market cap is $335.22 million. The stock has a 50 day moving average price of $16.28 and a 200 day moving average price of $16.85.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.11. On average, equities research analysts anticipate that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current fiscal year.

In related news, SVP Natalie Mcclure sold 36,000 shares of the stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $18.50, for a total transaction of $666,000.00. Following the sale, the senior vice president now directly owns 21,006 shares in the company, valued at approximately $388,611. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A number of large investors have added to or reduced their stakes in the company. Strs Ohio raised its stake in Adamas Pharmaceuticals by 46.9% in the fourth quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock worth $1,127,000 after buying an additional 12,700 shares during the period. Russell Frank Co raised its stake in Adamas Pharmaceuticals by 119.8% in the fourth quarter. Russell Frank Co now owns 83,773 shares of the specialty pharmaceutical company’s stock worth $2,395,000 after buying an additional 45,652 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Adamas Pharmaceuticals by 585.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 69,411 shares of the specialty pharmaceutical company’s stock worth $1,966,000 after buying an additional 59,285 shares during the period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.